Analysts Expect TRACON Pharmaceuticals Inc (TCON) Will Announce Earnings of -$0.45 Per Share

Equities analysts predict that TRACON Pharmaceuticals Inc (NASDAQ:TCON) will announce earnings of ($0.45) per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for TRACON Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.35) and the lowest estimate coming in at ($0.64). TRACON Pharmaceuticals also reported earnings of ($0.45) per share in the same quarter last year. The business is scheduled to issue its next quarterly earnings results on Tuesday, February 27th.

According to Zacks, analysts expect that TRACON Pharmaceuticals will report full year earnings of ($1.21) per share for the current year, with EPS estimates ranging from ($1.40) to ($1.11). For the next year, analysts expect that the firm will report earnings of ($0.80) per share, with EPS estimates ranging from ($1.75) to $0.63. Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that cover TRACON Pharmaceuticals.

Separately, Zacks Investment Research lowered TRACON Pharmaceuticals from a “buy” rating to a “hold” rating and set a $4.00 target price on the stock. in a research note on Friday, January 5th.

TRACON Pharmaceuticals (NASDAQ TCON) opened at $2.20 on Wednesday. TRACON Pharmaceuticals has a 52 week low of $2.00 and a 52 week high of $4.70. The company has a quick ratio of 3.80, a current ratio of 3.80 and a debt-to-equity ratio of 0.24. The stock has a market capitalization of $38.53, a PE ratio of -1.80 and a beta of 2.06.

Institutional investors and hedge funds have recently bought and sold shares of the business. 683 Capital Management LLC boosted its holdings in TRACON Pharmaceuticals by 49.7% in the fourth quarter. 683 Capital Management LLC now owns 1,490,000 shares of the biopharmaceutical company’s stock worth $4,992,000 after acquiring an additional 495,000 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in TRACON Pharmaceuticals by 73.0% in the fourth quarter. Renaissance Technologies LLC now owns 264,700 shares of the biopharmaceutical company’s stock worth $887,000 after acquiring an additional 111,700 shares in the last quarter. X Square Capital LLC acquired a new stake in TRACON Pharmaceuticals in the fourth quarter worth about $436,000. Finally, Candriam Luxembourg S.C.A. acquired a new stake in TRACON Pharmaceuticals in the third quarter worth about $450,000. Institutional investors own 36.27% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Analysts Expect TRACON Pharmaceuticals Inc (TCON) Will Announce Earnings of -$0.45 Per Share” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another publication, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this report can be read at https://www.dispatchtribunal.com/2018/02/21/analysts-expect-tracon-pharmaceuticals-inc-tcon-will-announce-earnings-of-0-45-per-share.html.

About TRACON Pharmaceuticals

TRACON Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (wet AMD) and fibrotic diseases. The Company’s research focuses on antibodies that bind to the endoglin receptor, which is essential to angiogenesis (the process of new blood vessel formation) and a contributor to fibrosis (tissue scarring).

Get a free copy of the Zacks research report on TRACON Pharmaceuticals (TCON)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for TRACON Pharmaceuticals (NASDAQ:TCON)

Receive News & Ratings for TRACON Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TRACON Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply